AMPH

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

24.900

Open

24.320

VWAP

24.72

Vol

510.68K

Mkt Cap

1.17B

Low

24.200

Amount

12.62M

EV/EBITDA(TTM)

5.98

Total Shares

48.90M

1.51B

EV/OCF(TTM)

7.84

P/S(TTM)

1.71

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

176.93M

-2.99%

0.764

-18.72%

187.66M

-1.86%

0.836

-12.92%

190.66M

+2.22%

0.824

-10.43%

Estimates Revision

The market is revising Downward the revenue expectations for Amphastar Pharmaceuticals, Inc. (AMPH) for FY2025, with the revenue forecasts being adjusted by -3.98% over the past three months. During the same period, the stock price has changed by -19.15%.

Revenue Estimates for FY2025

Revise Downward

-3.98%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-11.32%

In Past 3 Month

Stock Price

Go Down

-19.15%

In Past 3 Month

5 Analyst Rating

48.83% Upside

Wall Street analysts forecast AMPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMPH is 37.00 USD with a low forecast of 31.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

48.83% Upside

Current: 24.860

Low

31.00

Averages

37.00

High

45.00

48.83% Upside

Current: 24.860

Low

31.00

Averages

37.00

High

45.00

Wells Fargo

Cerena Chen

Buy

Maintains

$40 → $35

2025-05-08

Reason

Wells Fargo

Cerena Chen

Price Target

$40 → $35

2025-05-08

Maintains

Buy

Reason

Needham

Serge Belanger

Hold

Reiterates

n/a

2025-04-10

Reason

Needham

Serge Belanger

Price Target

n/a

2025-04-10

Reiterates

Hold

Reason

Piper Sandler

David Amsellem

Hold

Maintains

$36 → $32

2025-03-21

Reason

Piper Sandler

David Amsellem

Price Target

$36 → $32

2025-03-21

Maintains

Hold

Reason

Piper Sandler analyst David Amsellem lowered the firm's price target on Amphastar to $32 from $36 and keeps a Neutral rating on the shares. Though the firm could envision becoming more constructive to the extent that it sees key generic pipeline opportunities bear fruit, Piper nonetheless "cannot gloss over competitive challenges that are likely to pressure the top-line/EBITDA this year."

Piper Sandler

David Amsellem

Buy

Hold

Downgrades

$66 → $36

2025-02-04

Reason

Piper Sandler

David Amsellem

Price Target

$66 → $36

2025-02-04

Downgrades

Buy

Hold

Reason

Wells Fargo

Joe Quatrochi

Buy

Initiates

$55

2024-11-22

Reason

Wells Fargo

Joe Quatrochi

Price Target

$55

2024-11-22

Initiates

Buy

Reason

Wells Fargo initiated coverage of Amphastar with an Equal Weight rating and $55 price target. The firm likes the setup heading into 2025, saying Amphastar could have 2-3 new launches over the next 12 months, "yet is trading as if there is no pipeline." Amphastar has a solid commercial business and just a few pipeline wins could drive long-term growth, the analyst tells investors in a research note. Wells sees 20% upside in the shares as the company enters a new product cycle.

Piper Sandler

David Amsellem

Buy

Maintains

$71 → $66

2024-08-08

Reason

Piper Sandler

David Amsellem

Price Target

$71 → $66

2024-08-08

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Amphastar Pharmaceuticals Inc (AMPH.O) is 7.70, compared to its 5-year average forward P/E of 16.54. For a more detailed relative valuation and DCF analysis to assess Amphastar Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

16.54

Current PE

7.70

Overvalued PE

22.18

Undervalued PE

10.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

9.18

Current EV/EBITDA

6.03

Overvalued EV/EBITDA

11.02

Undervalued EV/EBITDA

7.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

2.65

Current PS

1.51

Overvalued PS

3.20

Undervalued PS

2.10